Orphan Drugs Market, By Drug Type (Biological and Non- Biological), By Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Other Top Selling Drugs), By Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Other Disease Types), By Phase (Phase I, Phase II, Phase III, and Phase IV), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Orphan drugs are the pharmaceutical mediators which are developed to treat rare medical conditions. Orphan drugs would not be able to earn profit because the orphan drugs are used to treat the rare diseases. It can only produce profit by the involvement of government assistant. Orphan drugs use to diagnoses and to prevent the diseases. Orphan drugs are not developed in industry, but it is generated for the public welfare. An orphan drug may be a pharmaceutical agent developed to treat medical conditions which, because they're so rare, wouldn't be profitable to supply without government assistance. The conditions are mentioned as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it's a matter of public policy in many countries and has yielded medical breakthroughs which may not otherwise are achieved, thanks to the economics of drug research and development. In the U.S. and therefore the EU, it's easier to realize marketing approval for an orphan drug. There could also be other financial incentives, like an extended period of exclusivity, during which the producer has sole rights to plug the drug. All are intended to encourage development of medicine which might otherwise lack sufficient profit motive to draw in corporate research budgets and personnel. The Global Orphan Drugs Market is estimated to be US$ 869.6 million by 2030 with a CAGR of 10.4% during the forecast period.

                                               

Orphan drugs can treat various diseases

Orphan drugs market is extensively high for orphan drug developers which is the major propelling factor for the growth of target market. In addition, the orphan drugs can treat the diseases type such as cardiology, oncology, and hematology, neurology which is the boosting factor for the growth of global market. As per the data published by WHO (World’s Health Organization), globally in 2016, cardiovascular diseases (CVD) are the main cause of death, around 17.9 million people died due to CVDs, which represented 31% of all deaths, globally.

Increasing prevalence in rare diseases

Additionally, Increases prevalence in the rare diseases is another fuelling factor for the growth of global market. Moreover, favorable government policies on the use of orphan drugs which is further propelling factor for the growth of the target market. However, high cost of pre patient restrain the growth of the global market. Furthermore, limited patient pool for the product marketing and clinical trials hampers growth of the target market. Nevertheless, increase in the government or FDA approval for the orphan drugs can create an opportunity for the growth of global orphan drugs market.

                                             

The global orphan drugs market is segmented based on drug type, disease, disease type, phase, and region.

On the basis of drug type, the global orphan drugs market is segmented into biological and non- biological. Biological drug type segment is expected to register the highest market growth during the forecast period. On the basis of top selling drugs, the target market is segmented into revlimid, rituxan, copaxone, opdivo, keytruda, imbruvica, avonex, sensipar, soliris, and other top selling drugs. Based on disease type, the global market is classified into oncology, hematology, neurology, cardiovascular, and other disease types. Oncology is the main disease segment which generates the largest revenue each year over the forecast period. On the basis of phase segment, the target market divided into phase I, phase II, phase III, and phase IV.

Regional Insights:

                                  

For detailed understanding of market dynamics, based on region the global orphan drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in North America region is seen to have a matured growth since this market correlates with the increasing growth rate of orphan disease. In North America region is the dominating region due to the U.S. is the largest share of market holder of the orphan drugs. In U.S., FDA gives approval to the specific indication, tax credits for orphan drugs.

                                         

Attribute	Details
Base year for estimation	2020
Forecast period	2020 – 2030
Market representation	Revenue in USD Million & CAGR from 2020 – 2030
Market Segmentation	By Drug Type- Biological And Non- Biological By Top Selling Drug- Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, And Other Top Selling Drugs By Disease Type- Oncology, Hematology, Neurology, Cardiovascular, And Other Disease Types By Phase Type- Phase I, Phase II, Phase III, And Phase IV
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Detailed Segmentation:

Global Orphan Drugs Market, By Drug Type:

• Biological
• Non- Biological

Global Orphan Drugs Market, By Top Selling Drugs:

• Revlimid
• Rituxan
• Copaxone
• Opdivo
• Keytruda
• Imbruvica
• Avonex
• Sensipar
• Soliris
• Other Top Selling Drugs

Global Orphan Drugs Market, By Disease Type:

• Oncology
• Hematology
• Neurology
• Cardiovascular
• Other Disease Types

Global Orphan Drugs Market, By Phase Type:

• Phase I
• Phase II
• Phase III
• Phase IV

Global Orphan Drugs Market, By Region:

• • • North America
      • North America Orphan Drugs Market, By Drug Type
      • North America Orphan Drugs Market, By Top Selling Drugs
      • North America Orphan Drugs Market, By Disease Type
      • North America Orphan Drugs Market, By  Phase Type
      • North America Orphan Drugs Market, By Country
        • U.S.
        • Canada
    • Europe
      • Europe Orphan Drugs Market, By Drug Type
      • Europe Orphan Drugs Market, By Top Selling Drugs
      • Europe Orphan Drugs Market, By Disease Type
      • Europe Orphan Drugs Market, By Phase Type
      • Europe Orphan Drugs Market, By Country
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Asia Pacific Orphan Drugs Market, By Drug Type
      • Asia Pacific Orphan Drugs Market, By Top Selling Drugs
      • Asia Pacific Orphan Drugs Market, By Disease Type
      • Asia Pacific Orphan Drugs Market, By Phase Type
      • Asia Pacific Orphan Drugs Market, By Country
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Latin America Orphan Drugs Market, By Drug Type
      • Latin America Orphan Drugs Market, By Top Selling Drugs
      • Latin America Orphan Drugs Market, By Disease Type
      • Latin America Orphan Drugs Market, By Phase Type
      • Latin America Orphan Drugs Market, By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Middle East & Africa Orphan Drugs Market, By Drug Type
      • Middle East & Africa Orphan Drugs Market, By Top Selling Drugs
      • Middle East & Africa Orphan Drugs Market, By Disease Type
      • Middle East & Africa Orphan Drugs Market, By Phase Type
      • Middle East & Africa Orphan Drugs Market, By Country
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

                                                                                    

The key players operating the global orphan drugs market involves AbbVie Inc., Celgene Corporation, Biogen, Teva Pharmaceutical Industries, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Amgen, Merck & Co. Inc., Jazz Pharmaceuticals Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the drug types in order to gain competitive edge in the target market.

• • AbbVie Inc.
    • • Company Overview
• • • • • • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Biogen
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Teva Pharmaceutical Industries
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • F. Hoffmann-La Roche AG
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Bristol-Myers Squibb Company
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Alexion Pharmaceuticals
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Amgen
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Merck & Co. Inc.
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Jazz Pharmaceuticals
        • • Company Overview
          • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
    • • • • Drug Type Portfolio
          • Key Highlights
          • Financial Performance
      • Celgene Corporation
        • • Company Overview

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for Orphan Drugs Strategies
     • Key Questions this Study will Answer

     • Global Orphan Drugs Market, By Drug Type:

       • Biological
       • Non- Biological

       Global Orphan Drugs Market, By Top Selling Drugs:

       • Revlimid
       • Rituxan
       • Copaxone
       • Opdivo
       • Keytruda
       • Imbruvica
       • Avonex
       • Sensipar
       • Soliris
       • Other Top Selling Drugs

       Global Orphan Drugs Market, By Disease Type:

       • Oncology
       • Hematology
       • Neurology
       • Cardiovascular
       • Other Disease Types

       Global Orphan Drugs Market, By Phase Type:

       • Phase I
       • Phase II
       • Phase III
       • Phase IV
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Orphan Drugs Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

 

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• • Celgene Corporation

  • Biogen

  • Teva Pharmaceutical Industries

  • F. Hoffmann-La Roche AG

  • Bristol-Myers Squibb Company

  • Alexion Pharmaceuticals

  • Amgen

  • Merck & Co. Inc.

  • Jazz Pharmaceuticals

1. The Last Word
   • Future Impact
   • About Us
   • Contact